Definium Therapeutics develops psychedelic-based therapeutics for psychiatric and neurological disorders. Backed by North Carolina Biotechnology Center.
About the role
Together we are moving psychiatry forward—beyond better, into a boundless future. Join us! We are seeking a Director, Talent Acquisition - Commercial to help build and scale the recruiting strategy for Definium’s first commercial organization. Reporting to the Senior Director, Talent Acquisition, this individual will serve as a strategic, hands-on partner to Commercial leadership, supporting launch readiness through thoughtful workforce planning, strong talent pipelines, and disciplined recruiting execution.
What they're looking for
- Bachelor’s degree required
- 8+ years of progressive talent acquisition experience supporting biotechnology, pharmaceutical, life sciences, healthcare, or similarly complex organizations
- Experience recruiting for commercial, sales, or field-based roles required, direct experience supporting commercial launches or team expansion strongly preferred
- Demonstrated ability to partner with and influence senior leaders while balancing business priorities, candidate experience, and recruiting discipline
- Experience building recruiting processes, programs, reporting, and talent pipelines in high-growth or evolving environments
- Strong working knowledge of commercial talent markets, field-based recruiting models, and external search firm management
More about this role
Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale.
Our lead product candidate, lysergide tartrate (our proprietary orally disintegrating tablet form of lysergide (LSD) D-tartrate), represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges.
Guided by the recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq...
Browse similar: Startup jobs · Remote jobs